Review



single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system  (Sequenom)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Sequenom single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system
    Single Nucleotide Extension Reaction With Allele Detection By Mass Spectrometry Sequenom Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/modified+single+nucleotide+extension+reaction+with+allele+detection+by+mass+spectrometry+sequenom+massarray+system/pmc06869631-79-12-14
    Average 90 stars, based on 1 article reviews
    single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Mass Spectrometry:

    Article Title: Influences of a DRD2 polymorphism on updating of long‐term memory representations and caudate BOLD activity: Magnification in aging
    Article Snippet: .. Genotyping was conducted with a single‐nucleotid extention reaction, with allele detection by mass spectrometry (Sequenom MassArray system; Sequenom, San Diego, CA). ..

    Article Title: The Tachykinin Receptor 3 Is Associated With Alcohol and Cocaine Dependence
    Article Snippet: .. The direction of transcription and the exons are indicated ... Genotyping of the 30 SNPs was done using a modified single nucleotide extension reaction with allele detection by mass spectrometry (Sequenom MassArray system; Sequenom, San Diego, CA). .. The assays were designed and run with either of 2 formats, hME TM or iPLEX TM (Sequenom, San Diego, CA).

    Article Title: Lack of association of alcohol dependence and habitual smoking with catechol-O-methyltransferase.
    Article Snippet: Objective: To test whether variation in the gene encoding the enzyme catechol-O-methyltransferase (COMT), which catalyzes the breakdown of dopamine and other catecholamine neurotransmitters, is associated with the risk for alcohol dependence and habitual smoking.. Methods: Single nucleotide polymophisms (SNPs) were genotyped in a sample of 219 multiplex alcohol-dependent families of European American descent from the Collaborative Study on the Genetics of Alcoholism (COGA).. Family-based tests of association were performed to evaluate the evidence of association between the 18 SNPs distributed throughout COMT, including the functional Val158Met polymorphism, and the phenotypes of alcohol dependence, early onset alcohol dependence, habitual smoking, and comorbid alcohol dependence and habitual smoking.

    Modification:

    Article Title: The Tachykinin Receptor 3 Is Associated With Alcohol and Cocaine Dependence
    Article Snippet: .. The direction of transcription and the exons are indicated ... Genotyping of the 30 SNPs was done using a modified single nucleotide extension reaction with allele detection by mass spectrometry (Sequenom MassArray system; Sequenom, San Diego, CA). .. The assays were designed and run with either of 2 formats, hME TM or iPLEX TM (Sequenom, San Diego, CA).

    Article Title: Lack of association of alcohol dependence and habitual smoking with catechol-O-methyltransferase.
    Article Snippet: Objective: To test whether variation in the gene encoding the enzyme catechol-O-methyltransferase (COMT), which catalyzes the breakdown of dopamine and other catecholamine neurotransmitters, is associated with the risk for alcohol dependence and habitual smoking.. Methods: Single nucleotide polymophisms (SNPs) were genotyped in a sample of 219 multiplex alcohol-dependent families of European American descent from the Collaborative Study on the Genetics of Alcoholism (COGA).. Family-based tests of association were performed to evaluate the evidence of association between the 18 SNPs distributed throughout COMT, including the functional Val158Met polymorphism, and the phenotypes of alcohol dependence, early onset alcohol dependence, habitual smoking, and comorbid alcohol dependence and habitual smoking.



    Similar Products

    90
    Sequenom massarray sequenom detection
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc09085879-184-7-8
    Average 90 stars, based on 1 article reviews
    massarray sequenom detection - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Sequenom snps detected by sequenom massarray rs1000 platform
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Snps Detected By Sequenom Massarray Rs1000 Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/massarray+rs1000/pm33127268-102-12-16
    Average 90 stars, based on 1 article reviews
    snps detected by sequenom massarray rs1000 platform - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Sequenom mass spectrometry-based detection (sequenom massarray platform)
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometry Based Detection (Sequenom Massarray Platform), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc06107190-119-25-28
    Average 90 stars, based on 1 article reviews
    mass spectrometry-based detection (sequenom massarray platform) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Sequenom detection limitation of sequenom massarray
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Detection Limitation Of Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc05863829-107-32-31
    Average 90 stars, based on 1 article reviews
    detection limitation of sequenom massarray - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Sequenom mass spectrometric detection (sequenom massarray)
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometric Detection (Sequenom Massarray), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pm26003169-313-9-12
    Average 90 stars, based on 1 article reviews
    mass spectrometric detection (sequenom massarray) - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Sequenom mass spectrometric detection sequenom massarray
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Mass Spectrometric Detection Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc04258414-60-7-10
    Average 90 stars, based on 1 article reviews
    mass spectrometric detection sequenom massarray - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Sequenom single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system
    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
    Single Nucleotide Extension Reaction With Allele Detection By Mass Spectrometry Sequenom Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+sequenom+detection/modified+single+nucleotide+extension+reaction+with+allele+detection+by+mass+spectrometry+sequenom+massarray+system/pmc06869631-79-12-14
    Average 90 stars, based on 1 article reviews
    single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Journal: Cell Death & Disease

    Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

    doi: 10.1038/s41419-022-04895-6

    Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

    Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

    Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing